<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Articles</title>
    <link rel="stylesheet" href="articles.css">
</head>
<body>
    <h1>Blogs & Articles</h1>

    <div class="search-blog">
        <form>
          <div class="search">
            
            <input type="text" id="myInput" onkeyup="myFunction()" placeholder="Search"
             autocomplete="off" spellcheck="false" role="combobox" aria-live="polite">
      <!--        
             <button class="search-button"><img src="/imgs/icons8-search-64.png" alt=""></button> -->
      
            <ul class="search-bar-items" id="myUL">
                <li><a href="#altuviiio">Altuviiio</a></li>
                <li><a href="#bleedaid">BleedAid</a></li>
                <li><a href="#Altuviiio">Altuviiio</a></li>
                <li><a href="#trials">Cliinical trials</a></li>
                <li><a href="#pain">Pain Approach in Hemophilia</a></li>
                <li><a href="#half-life">FVIII</a></li>
                <li><a href="#treatment">Treatment history</a></li>
                <li><a href="#agent">Concizumab</a></li>
                <li><a href="#SDM">Shared decision making</a></li>
                <!-- <li><a href="">Altuviiio</a></li>
                <li><a href="">Altuviiio</a></li> -->
            </ul>
            
          </div>
        </form>
      </div>

    <section class="marg" id="bleedaid">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>BLEED AID</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0021.jpg">
        </div><br>
        <p><strong>Welcome</strong> to the BleedAid WhatsApp Community! <br><br> We're thrilled that you've joined our network dedicated to connecting healthcare professionals managing hemophilia and other bleeding disorders worldwide. <br><br>

            Our goal is to foster collaboration, share knowledge, and improve patient outcomes through open communication and evidence-based practices.<br><br>
            
            As members of this group, we encourage active participation in discussions related to clinical management, research updates, case studies, and more. <br><br>
            
            By sharing your expertise and experiences with one another, we can collectively advance the field of hemostasis and ensure better care for those living with these conditions.<br><br>
            
            Please feel free to introduce yourself by posting a brief bio or any relevant information about your background and interests within the realm of bleeding disorders. <br><br>
            
            Let's work together towards improving the lives of patients affected by hemophilia and similar diseases.<br><br>
            
            Thank you again for joining us at BleedAid, where we are committed to making a difference in the world of bleeding disorder</p>  
    </section>
    <section class="marg" id="altuviiio">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>Altuviiio for Haemophila</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0012.jpg">
        </div><br>
        <p><strong>F</strong>DA approves once-weekly ALTUVIIIO‚Ñ¢, a new class of factor VIII therapy  from Sanofi for hemophilia A that offers significant bleed protection. <br><br>

        ALTUVIIIO is administered parenterally  I am curious about the adoption of this treatment within the global hemophilia community, particularly considering their familiarity with subcutaneous treatments like Emicizumab. <br><br>

        Do the advantages of a once-weekly injection outweigh the disadvantages of intravenous administration with ALTUVIIIO? I would appreciate reading  your insights on this matter. <br><br> 
        
        ALTUVIIIO is administered parenterally  I am curious about the adoption of this treatment within the global hemophilia community, particularly considering their familiarity with subcutaneous treatments like Emicizumab. <br><br> 
        
        Do the advantages of a once-weekly injection outweigh the disadvantages of intravenous administration with ALTUVIIIO? I would appreciate reading  your insights on this matter.</p>  
    </section>
    <section class="marg" id="Altuviiio">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>Altuviiio for Haemophila</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0013.jpg">
        </div><br>
        <p><strong>ALTUVIIIO </strong>is administered parenterally  I am curious about the adoption of this treatment within the global hemophilia community, particularly considering their familiarity with subcutaneous treatments like Emicizumab. <br><br>
        
        Do the advantages of a once-weekly injection outweigh the disadvantages of intravenous administration with ALTUVIIIO? I would appreciate reading  your insights on this matter.
        </p>  
    </section>
    <section class="marg" id="trials">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>Phase I Clinical Trial on Altuviiio</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0014.jpg">
        </div><br>
        <p><strong>T</strong>houghts on this üëÜüèΩüëÜüèΩüëÜüèΩüëÜüèΩ <br><br>
            
            
            The uptake of ALTUVIIIO, a novel once-weekly Factor VIII replacement therapy, appears promising but should be considered alongside existing treatment options. <br><br>
            
            Unlike Emicizumab, which provides continuous coverage via a biweekly or once monthly subcutaneous injection, ALTUVIIIO offers higher-for-longer levels of Factor VIII, reaching near-normal to normal ranges for most of the week[2]. <br><br>
            
            In a Phase 3 study, ALTUVIIIO reduced the annualized bleeding rate (ABR) by 77% compared to previous prophylaxis, while achieving a mean ABR of 0.70[1]. <br><br>
            
            However, the convenience of subcutaneous administration with Emicizumab might still appeal to some patients despite the need for twice-monthly injections. <br><br>
            
            *Ultimately, the choice between ALTUVIIIO and Emicizumab depends on individual preferences regarding administration method, treatment goals, and potential risks such as the development of inhibitors[5].
            *<br><br>
            Sources : <br><br>
            [1] Press Release: FDA approves once-weekly ALTUVIIIO‚Ñ¢, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection <a href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-02-23-21-00-00-2614759">click here</a> <br><br>
            [2] ALTUVIIIO is the first and only once-weekly Factor VIII replacement therapy of its kind <a href="https://www.altuviiio.com">click here</a> <br><br>
            [3] Altuviiio Approved as Once-Weekly Factor VIII Therapy for Hemophilia A <a href="https://www.empr.com/home/news/altuviiio-approved-as-once-weekly-factor-viii-therapy-for-hemophilia-a/ ">click here</a><br><br>
            [4] Engineered to last longer <a href="https://www.altuviiio.com/how-does-altuviiio-work">Click to find out more</a> <br><br>
            [5] ALTUVIIIO (Antihemophilic Factor (Recombinant), Fc-Von Willebrand Factor - XTEN Fusion Protein-ehtl) for Hemophilia A - For US Healthcare Professionals <a href="https://www.altuviiiohcp.com">click here</a></p>  
    </section>
    <section class="marg" id="pain">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>Pain Approach In Haemophila</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0015.jpg">
        </div><br>
        <p><strong>T</strong>reaters and physical therapist on this channel. Pain management should really be a thing in the management of  haemophilic arthropathy. <br><br>
            
        This algorithm  as proposed by Cuesta-Barriuso R et al, 2022 is simple and can be applied in most clinical setting. <a href="https://www.dovepress.com/hemophilic-arthropathy-barriers-to-early-diagnosis-and-management-peer-reviewed-fulltext-article-JBM">click here</a> for an

            Interesting review</p>  
    </section>
    <section class="marg" id="half-life">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>Half-life on FVIII (Altuviiio)</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0018.jpg">
        </div><br>
        <p><strong>Figure 1.</strong> <br><br>
            Effect of half-life on FVIII level following a bolus infusion. Following a standard weight-based bolus infusion of 30‚ÄâIU/kg in patients aged 10‚Äì65‚Äâyears, the time taken for FVIII to reach 1% can vary by as much as 59‚Äâh within the normal range of half-life. <br><br>
            
            A short half-life is the 5th percentile and a long half-life is the 95th percentile of the normal range. Figure adapted from Collins et al.10
            
            FVIII, factor VIII; IU, international unit.</p>  
    </section>
    <section class="marg" id="treatment">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>Haemophila Treatment History</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0019.jpg">
        </div><br>
        <p><strong>K</strong>now your haemophilia treatment  history and this paper by Ozelo & Hayakawa elaborates the historical aspect of treatment agents as well as the novel haemophilia therapies and how they impact treatment 
            Ozelo MC, Yamaguti-Hayakawa GG. <br><br>
         Impact of novel hemophilia therapies around the world. Res Pract Thromb Haemost. 2022; 6:e12695. doi:10.1002/rth2.12695</p>  
    </section>
    <section class="marg" id="agent">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>Rebalancing Agent - [Concizumab]</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0020.jpg">
        </div><br>
        <p>Rebalancing agent. New kid on the block Concizumab <br><br>

            <strong>Concizumab</strong> is a novel investigational drug currently being developed for the treatment of hemophilia A and hemophilia B. It is a monoclonal antibody that targets and inhibits tissue factor pathway inhibitor (TFPI), a protein that regulates blood clotting. <br><br>
            
            Here are some key points to know about concizumab: <br><br>
            
            1. Mechanism of action: Concizumab works by blocking TFPI, which is a natural inhibitor of the blood coagulation process. By inhibiting TFPI, concizumab can potentially enhance blood clotting and reduce bleeding episodes in patients with hemophilia. <br><br>
            
            2. Hemophilia A and B:  Concizumab has shown promise in both types of hemophilia. <br><br>
            
            3. Clinical trials: Concizumab has undergone several clinical trials to evaluate its safety and efficacy.
            [25/02, 10:46 am] null: Clinical trials: Concizumab has These trials have included both adults and children with hemophilia A or B. Results from early studies have shown a reduction in bleeding episodes and an improvement in clotting factors. <br><br>
            
            4. Potential benefits: If approved, concizumab could offer a new treatment option for patients with hemophilia A or B. It has the potential to reduce bleeding episodes, improve quality of life, and reduce the need for factor replacement therapy. <br><br>
            
            5. Safety considerations: As with any medication, concizumab has potential side effects. Common side effects observed in clinical trials include injection site reactions, headaches, and joint pain. Long-term safety data is still being evaluated. <br><br>
            
            It's important to note that concizumab is still under investigation and has not yet been approved by regulatory authorities. Patients who are interested in concizumab should consult with their healthcare provider for the latest information and updates on its development.</p>  
    </section>
    <section class="marg" id="SDM">
        <div class="art-head">
            <a href="#"><p>Haemophila</p></a>
            <h2>World Federation of Haemophilia - [SDM]</h2>
        </div>
        <div class="img-cont">
            <img src="/imgs/IMG-20240303-WA0022.jpg">
        </div><br>
        <p><strong>A</strong>s a Treater or HCP involved in Haemophilia management, do you know about the <b>shared decision-making model of patient care?</b> <br><br>

            World Federation of Haemophilia is currently conducting training in the Americas on shared decision making model of patient care. <br><br>
            
            Visit the WFH website to know more about this tool</p>  
    </section>



    <nav>
        <ul>
          <li><a href="/home.html" id="home-link">Home</a></li>
          <li><a href="/articles.html" id="articles-link">Articles</a></li>
          <li><a href="/profile.html" id="profile-link">Profile</a></li>
        </ul>
    </nav>

    <script src="/js.js"></script>
</body>
</html>